Orange Book product · Generic (ANDA)
CASPOFUNGIN ACETATE
CASPOFUNGIN ACETATE
At a glance
Jul 18, 2025
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 18, 2025
11 mo ago
Today
Pharmaceutical detail
Active ingredient
CASPOFUNGIN ACETATE
Strength
50MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
AP
Application
ANDA 216506
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CASPOFUNGIN ACETATE
- 2016CASPOFUNGIN ACETATEBrand (NDA)
NDA 206110 · FRESENIUS KABI USA
- 2001CANCIDASBrand (NDA)
NDA 021227 · MERCK
- 2021CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 211263 · AREVA PHARMS
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 209489 · CIPLA
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 205923 · XELLIA PHARMS APS
- 2018CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 200833 · HENGRUI PHARMA
- 2017CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 207092 · GLAND
- 2017CASPOFUNGIN ACETATEGeneric (ANDA)
ANDA 207650 · PHARMOBEDIENT
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
